Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$437K Sell
70,887
-460,843
-87% -$3.83M ﹤0.01% 2895
2025
Q4
$5.54M Buy
531,730
+456,803
+610% +$4.58M ﹤0.01% 1868
2025
Q3
$674K Sell
74,927
-36,996
-33% -$325K ﹤0.01% 2795
2025
Q2
$1.45M Sell
111,923
-108,252
-49% -$1.63M ﹤0.01% 2435
2025
Q1
$5.56M Sell
220,175
-912
-0.4% -$27.1K ﹤0.01% 1872
2024
Q4
$7.6M Sell
221,087
-34,555
-14% -$1.56M ﹤0.01% 1753
2024
Q3
$12.6M Sell
255,642
-303,471
-54% -$15.5M ﹤0.01% 1465
2024
Q2
$33.6M Sell
559,113
-186,280
-25% -$10.6M 0.01% 825
2024
Q1
$38.4M Buy
745,393
+49,688
+7% +$2.44M 0.01% 763
2023
Q4
$28.1M Buy
695,705
+264,228
+61% +$7.75M 0.01% 930
2023
Q3
$12M Buy
431,477
+310,992
+258% +$9.27M ﹤0.01% 1362
2023
Q2
$3.47M Buy
120,485
+53,133
+79% +$1.18M ﹤0.01% 2091
2023
Q1
$1.12M Buy
67,352
+3,474
+5% +$49.1K ﹤0.01% 2570
2022
Q4
$810K Sell
63,878
-3,587
-5% -$43.6K ﹤0.01% 2759
2022
Q3
$810K Buy
67,465
+2,254
+3% +$31K ﹤0.01% 2834
2022
Q2
$918K Buy
65,211
+40,301
+162% +$532K ﹤0.01% 2823
2022
Q1
$290K Buy
+24,910
New +$299K ﹤0.01% 3130

Other funds holding RXST

Nuveen's RXST Position: Q1 2026 in Review

Nuveen reduced its RxSight (RXST) stake by 87% in Q1 2026, selling an estimated $3.83M and leaving 70,887 shares worth $437K. The position accounts for ﹤0.01% of the portfolio, ranked #2895.

Nuveen first reported a position in RXST in Q1 2022 and has held it in 17 quarters since. The position peaked at $38.4M in Q1 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

  • Nuveen held 70,887 shares of RxSight worth $437K as of Q1 2026.
  • Nuveen sold 460,843 RxSight shares in Q1 2026, an estimated $3.83M.
  • RxSight made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2895 holding.
  • Nuveen first reported a position in RxSight in Q1 2022 and has held it in 17 quarters since.
  • Nuveen's RxSight position peaked at $38.4M in Q1 2024.
  • 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.